1Drop Diagnostics is a technology company.
1Drop Diagnostics is a technology company.
1Drop Diagnostics has raised $4.0M across 1 funding round.
1Drop Diagnostics has raised $4.0M in total across 1 funding round.
1Drop Diagnostics has raised $4.0M in total across 1 funding round.
1Drop Diagnostics Sàrl is a Swiss biotech company developing portable, non-invasive diagnostic devices that analyze biomarkers from a single drop of blood, enabling rapid, at-home testing for conditions like cardiovascular disease, infectious diseases, organ function, and autoimmune disorders.[1][4][5][6] Their core product, the 1DROP Health Reader, paired with disposable chips, delivers lab-quality results in 15 minutes via a smartphone app, serving consumers, patients, and healthcare providers seeking personalized health monitoring without clinic visits.[5][6] This solves the problem of inaccessible, slow diagnostics by empowering early detection, disease prevention, and treatment adjustment, with strong growth momentum including planned FDA 510(k) clearance and CE Mark by late 2024, shipping in early 2025.[1][6]
Founded in Neuchâtel, Switzerland (with a U.S. presence in Boston), 1Drop Diagnostics emerged from expertise in biosensors to address gaps in portable medical testing.[1][9] Led by biotech engineers, the idea crystallized around miniaturizing lab capabilities into a "milk carton-sized" device for real-time analysis of blood drops, starting with high-impact areas like cardiovascular and infectious diseases (e.g., COVID, HIV, Ebola).[4] Early traction came from collaborations with biosensor experts and recognition as a Top 100 Startup in Switzerland, prioritizing customer needs for rapid, multiplexed assays of proteins, nucleic acids, and peptides in disease research, drug development, and clinical use.[1]
(Note: Distinct from Korean firm 1drop Inc., which focuses on molecular PCR kits and smartphone biosensors for DNA/RNA detection.[2][3][7])
1Drop rides the point-of-care (POC) diagnostics and decentralized health wave, fueled by post-pandemic demand for at-home testing, telehealth, and precision medicine.[1][5][6] Timing aligns with aging populations, rising chronic diseases (e.g., cardiovascular, affecting 1 in 3 globally), and regulatory shifts favoring consumer diagnostics, as seen in FDA/CE pathways.[4][6] Market forces like biosensor miniaturization, AI-driven analytics, and smartphone ubiquity favor them, reducing healthcare costs and enabling real-time data for therapies/drug development.[1] They influence the ecosystem by democratizing access—shifting from centralized labs to patient-led monitoring—boosting outcomes in underserved areas and integrating with digital health platforms.[5]
Regulatory milestones (FDA/CE in 2025) position 1Drop for U.S./EU commercialization, expanding from pre-order chips to full test suites amid booming $50B+ POC market growth.[6] Trends like AI-enhanced biomarkers, wearable integration, and global health equity will propel them, potentially partnering with pharma for clinical trials or insurers for preventive care. Their influence could evolve from niche innovator to mainstream enabler of personalized healthcare, directly tying back to revolutionizing lives with that single, actionable drop of blood.[1][4][5]
1Drop Diagnostics has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Series A in October 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2018 | $4.0M Series A |